Industry News

Accuray Delivers First Commercial InCise MLC for CyberKnife M6 System

Accuray Incorporated (Nasdaq: ARAY) and Lancaster General Health announced that the first commercially available InCise Multileaf Collimator (MLC) for the CyberKnife M6 System has been received by Lancaster. The hospital selected the InCise MLC based on its ability to increase the system’s treatment efficiency and extend its unique capabilities to a broader range of patient cases.

Evaluation of the InCise MLC with the CyberKnife M6 system has been completed by two U.S. sites. Accuray is now working closely with its supply chain network to scale up manufacturing to meet commercial demand for the MLC.

The InCise MLC is the first multileaf collimator available on a robotic platform, the CyberKnife M6 System, designed to deliver stereotactic body radiation therapy (SBRT). Using its robotic range of motion and continuous image guidance, the system follows the target throughout the treatment process, delivering individualized treatment. The CyberKnife M6 System can be used to treat tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney, and may offer hope to patients with inoperable or surgically complex tumors, or who prefer a non-surgical option.

“This is an important milestone for Accuray. It represents an evolution in the CyberKnife System platform that we believe will lead to meaningful improvements in the treatment of cancer for clinicians and patients, and broaden the range of patients and tumors that can be treated,” said Joshua H. Levine, president and chief executive officer of Accuray. “For example, evaluations to date of the technical performance of the device indicate that its use may result in a 30% to 40% reduction in treatment times compared to current timeframes. Patients will experience enhanced comfort from spending less time on the treatment couch and clinicians will see efficiencies in their ability to plan and deliver SBRT.”